We report the successful treatment of autoimmune hypoglycemia in an 82-year-old non-diabetic Caucasian male with hydrothermally modified slow release corn starch, a product which is used in other conditions associated with hypoglycemia, most typically glycogen storage disease type I. An 82-year-old-Caucasian male presented with recurrent spontaneous hypoglycemia as low as 30 mg/dl following in-patient treatment for community acquired pneumonia. During a fasting-test, symptomatic hypoglycemia occurred. Plasma concentrations of c-peptide and insulin were considerably elevated. Autoimmune hypoglycemia was confirmed by the presence of insulin autoantibodies. While dietary restriction alone did not result in sufficient glucose control in this patient with autoimmune hypoglycemia, treatment with hydrothermally modified slow release corn starch led to stable euglycemia. This easy, well tolerated and non-invasive treatment may constitute a new therapeutic option for hypoglycemia in patients with autoimmune hypoglycemia who do not achieve sufficient control of hypoglycemia by dietary restriction alone.
INTRODUCTION
Autoimmune hypoglycemia (Hirata's disease) was first described by Hirata and Ishizu in 1972 (ref. 1) . In Japan, autoimmune hypoglycemia is the third leading cause for hypoglycemia. 1 However, in non-Asian populations, this condition is very rare. 1 In autoimmune hypoglycemia, autoantibodies bind to insulin, rendering it unable to exert its effect in lowering blood glucose concentration, resulting in postprandial hyperglycemia. In the fasted state, such bound insulin spontaneously dissociates from the autoantibodies, leading to a relative excess of insulin. Subsequently, hypoglycemia in the fasted state occurs. 1 We report the case of an 82-year old non diabetic Caucasian male with recurrent symptomatic hypoglycemic episodes due to autoimmune hypoglycemia. As dietary measures alone could not achieve sufficient blood glucose control in our patient, we initiated a therapy with slow release corn starch. Slow release corn starch has proved transformative as a therapeutic management in other conditions associated with hypoglycemia, including glycogen storage disease type I, type 1 diabetes mellitus and during endurance activity in athletes. [2] [3] [4] [5] A treatment regimen with slow release corn starch led to stable euglycemia in our patient with autoimmune hypoglycemia.
This easy, well tolerated and non-invasive treatment may constitute a new therapeutic option for hypoglycemia in patients with autoimmune hypoglycemia who do not achieve sufficient control of hypoglycemia by dietary restriction alone.
CASE REPORT
An 82-year-old Caucasian male was referred to us for further evaluation of recurrent hypoglycemia. Symptomatic hypoglycemic episodes commenced 2 months before his presentation following in-patient treatment for community acquired pneumonia. Hypoglycemic episodes occurred daily in the late afternoon and during night, with documented hypoglycemia as low as 30 mg/dl. Clinical symptoms of hypoglycemia promptly ceased after consumption of carbohydrates.
During a fasting-test, symptomatic hypoglycemia (50 mg/dl) occurred after 8 h. Plasma concentrations of c-peptide (14.7 ng/ml) and insulin (41000 μU/ml) were considerably elevated. Insulinoma was considered but no pancreatic mass could be identified via 68 Ga-DOTATATE PET/CT, endoscopic ultrasound or thin layer CT of the pancreas. Thus, autoimmune hypoglycemia was suspected. Autoimmune hypoglycemia was confirmed by the presence of insulin autoantibodies. Binding capacity of insulin autoantibodies was distinctly elevated (95%, normally o 15%).
In the absence of neoplastic, hematologic or concomitant autoimmune disease, we considered the previous episode of pneumonia as a trigger for autoimmune hypoglycemia in this patient, 6 given that there was no history of diabetes or previous exposure to insulin and insulin secretagogues.
Despite recommending a carbohydrate restricted diet, before treatment with slow release corn starch, nocturnal hypoglycemia occurred on a daily basis and stable euglycemia could only be achieved by continuous intravenous glucose administration during nighttime. Treatment with 60 g of slow release corn starch (Glycosade) at 2200 hours. resulted in stable euglycemia until early morning with glucose values ranging between 67 mg/dl and 92 mg/dl. During 4 days follow-up, no more documented episodes of hypoglycemia occurred. After being discharged from hospital, the patient was lost to follow-up.
DISCUSSION
Our 82-year-old Caucasian male patient suffered from autoimmune hypoglycemia following in-patient treatment for community acquired pneumonia. 6 In autoimmune hypoglycemia, autoantibodies binding to insulin render insulin unable to exert its effect in lowering blood glucose concentration, thus leading to postprandial hyperglycemia. 1 As such bound insulin spontaneously dissociates from the autoantibodies in the fasted state, a relative excess of insulin leads to subsequent hypoglycemia. 1 Interestingly, the prevalence of diabetes-associated autoantibodies seems to vary widely between different countries and only the presence of multiple such antibodies but not the isolated elevation of insulin autoantibodies predicts the future onset of glycemic imbalances in asymptomatic cohorts. In the absence of clinical symptoms of hypoglycemia, the presence of a single diabetes-associated autoantibody does not seem to be clinically significant. 7 Autoimmune hypoglycemia is characterized by extremely high insulin concentrations, usually 10-fold higher than the insulin concentration seen in insulinoma. 1 Autoimmune hypoglycemia is differentiated from organic hyperinsulinism (insulinoma and nesidioblastosis) and exogenous hyperinsulinism by the presence of insulin autoantibodies in the context of typical clinical and lab findings. 8 Furthermore, distinctly elevated binding capacity of insulin autoantibodies as observed in our patient (95%, normally o15%) is associated with an increased risk for hypoglycemic episodes. 1 In autoimmune hypoglycemia, the therapeutic aim is to minimize postprandial insulin release. In most cases, hypoglycemic episodes can be controlled by dietary restriction of fast acting carbohydrates and by ingesting small, frequent meals throughout the day. 9 Further treatment options include acarbose, immunosuppression and pancreatectomy. 1 However, despite recommending a carbohydrate restricted, low glycemic index and low glycemic load diet, our patient continued to suffer from hypoglycemic episodes in the early morning hours. We therefore initiated a therapy with hydrothermally modified slow release corn starch, a product that is typically used in other conditions associated with hypoglycemia like glycogen storage disease type I, type 1 diabetes mellitus and during endurance activity in athletes. [2] [3] [4] In patients with glycogenosis, slow release corn starch is superior to uncooked corn starch or other carbohydrates in preventing hypoglycemia due to its unique effect of blunting the insulin response and ensuring a constant glucose release for several hours. 3 Treatment with slow release corn starch has been shown to allow patients with glycogen storage disease to sleep through the night without the need for regular feeding or continuous intravenous glucose administration. 3 Since insulin secretion partly depends on the ratio of amylose/amylopectin in a meal, the higher quantity of amylopectin in slow release corn starch may convey additional effects on blunting the postprandial insulin release. 10 In our patient, a treatment regimen with 60 g of slow release corn starch once daily resulted in stable euglycemia. Given no more documented episodes of nocturnal hypoglycemia for four subsequent nights, our patient could be discharged from hospital.
CONCLUSION
To the best of our knowledge, hydrothermally modified slow release corn starch has not yet been described as a treatment option for hypoglycemia in autoimmune hypoglycemia. We believe that due to its ability to stabilize blood glucose concentrations, this easy, well tolerated and non-invasive treatment may constitute a new therapeutic option for autoimmune hypoglycemia in patients that do not achieve sufficient control of hypoglycemia by dietary restriction alone.
